Business View - February 2015 127
and medical centers treating the orphan diseases –
which could make the company more attractive to po-
tential outside investors.
Glioblastoma is the most common and aggressive
primary brain tumor in humans, representing about
17 percent of all primary tumors. Median survival for
adults on standard treatment is two to three years,
though the timeframe dips to 14.6 months in more ag-
gressive cases, where two-year survival is 30 percent.
A 2009 study said almost 10 percent of patients may
live five years or longer.
“We believe it is an attractive place to point invest-
ment dollars and believe that we can make a differ-
ence in terms of the quality of life and the survival of
cancer patients with a relatively rare disease,” Bacha
said. “The return on the investment, we believe, is very
attractive.
“The ability to access the market is very attractive.
And, of course, we wouldn’t be doing this unless we
believed that this drug, with its clinical history and our
understanding of the mechanism in a modern sense,
can really solve a problem.”
PREFERRED VENDORS
AlphoraResearch (
–
Provides
active pharmaceutical ingredient technology development
services for the scale-up of complex small molecules for
pharmaceutical and biotechnology companies. Core focus
is process chemistry and analytical services for early stage
development of pre-clinical and clinical candidates, where
speed and quality are paramount.
MarionWeinreb & Associates (
)
4289 1/2 Page Business View Magazine Ad
Client: Alphora Research
Dimensions: Half Page Horizontal ad: 7.5”Wide x 4.9” no bleed
905.403.0055 >
HEALTHCARE
